HIV Alters Plasma and M. tuberculosis-induced Cytokine

Production in Patients with Tuberculosis by Subramanyam, S et al.
JOURNAL OF INTERFERON & CYTOKINE RESEARCH 24:101–106 (2004)
© Mary Ann Liebert, Inc.
HIV Alters Plasma and M. tuberculosis-induced Cytokine
Production in Patients with Tuberculosis
S. SUBRAMANYAM, L.E. HANNA, P. VENKATESAN, K. SANKARAN, 
P.R. NARAYANAN, and S. SWAMINATHAN
ABSTRACT
To test the hypothesis that HIV infection brings about an alteration in the immune response to tuberculosis
(TB), mycobacterial antigen-induced production and plasma levels of the inflammatory cytokine interferon-g
(IFN-g) and its regulatory cytokines interleukin-12 (IL-12), IL-18, and IL-10 were determined in patients in-
fected dually with HIV and TB and compared with individuals with either disease and with healthy controls.
Peripheral blood mononuclear cells (PBMCs) of TB patients with HIV infection produced lesser amounts of
IFN-g and IL-12 compared with TB patients without HIV infection after in vitro stimulation with mycobac-
terial antigens. There was no difference in antigen-induced IL-18 production in TB patients with or without
HIV infection. The in vivo cytokine pattern did not correlate with that seen in vitro. Higher levels of IFN-g,
IL-12, and IL-18 were detected in the plasma of TB patients infected with HIV compared with TB patients
without HIV infection. The presence of significantly higher plasma levels of proinflammatory cytokines sug-
gests a greater degree of immune activation in individuals with HIV and TB, particularly those with low CD4
counts. In vitro IL-10 production by HIV-positive TB patients was similar to that of the HIV-negative TB
group and higher than in HIV-positive individuals without TB, but the plasma levels were similar. HIV in-




TUBERCULOSIS (TB) CONTINUES TO BE the most prevalentcause of death from an infectious agent globally, and its
interaction with HIV is having devastating effects.(1) HIV in-
fection has emerged as by far the most important of all the pre-
disposing factors for the development of TB(2) (primary or re-
activation),(3,4) and TB is often the sentinel illness of HIV
infection.(5) TB causes worsening of HIV disease status, in-
creases viral replication, decreases immunity, and hastens the
onset of AIDS.(6)
The pattern of cytokines produced by T lymphocytes plays
a central role in the susceptibility to TB. Activation of Th1
lymphocytes, interferon-g (IFN-g) production, and macro-
phage activation are crucial in the defense against mycobac-
teria.(7) On the other hand, Th2 cell activation and increased
interleukin-4 (IL-4) production have been associated with
poor clinical outcome after treatment.(8) HIV infection is as-
sociated with a profound deregulation of the immune system
and alterations in the cytokine profile.(9) The present study
was carried out to test the hypothesis that HIV infection
brings about an alteration in the host immune response to TB.
To this end, in vivo levels of the proinflammatory cytokine
IFN-g and its regulatory cytokines (IL-12, IL-18, and IL-10)
in plasma, as well as mycobacterial antigen-induced produc-
tion of these cytokines by peripheral blood mononuclear cells




Patients suspected of having HIV infection or TB were in-
vestigated at the Tuberculosis Research Centre, Chennai. The
diagnosis of TB was based on sputum smear examination for
acid-fast bacilli and confirmed by culture for Mycobacterium
tuberculosis. HIV infection was diagnosed using two rapid tests
(HIV Tridot, J. Mitra, New Delhi, India, and CombAids, Span
Tuberculosis Research Centre, Mayor V R Ramanathan Road, Chetput, Chennai-600031, India.
Diagnostics, Surat, India), and a positive result was confirmed
by an ELISA test (Enzaids, Span Diagnostics).
The study population comprised four groups of individuals:
(1) 29 HIV-seropositive patients with active TB (22 males and
7 females, age range 21–52 years, mean age 35 years), (2) 21
HIV-seronegative patients with TB (15 males and 6 females,
age range 18–70 years, mean age 42 years), (3) 26 HIV-seropos-
itive patients without active TB (19 males and 7 females, age
range 19–50 years, mean age 33 years), and (4) 22 healthy con-
trols (11 males and 11 females, age range 21–48 years, mean
age 32 years) who were laboratory workers in the Tuberculo-
sis Research Centre.
All HIV-positive patients tested positive for HIV-1, and 3 also
had HIV-2 co-infection. Among the TB patients, 1 had pleural ef-
fusion, and all the rest had sputum-positive pulmonary TB. The
group comprising HIV patients without TB was highly diverse.
The majority of the individuals in this group had other oppor-
tunistic infections, such as pneumonia, diarrhea, or central ner-
vous system (CNS) infections, and were being treated as 
inpatients in the Government Hospital for Thoracic Medicine,
Tambaram, Chennai at the time of the study. One person had hepa-
titis B co-infection, 1 was being treated for sexually transmitted
disease, and 4 were asymptomatic. The most common risk factor
for HIV infection in the study population was heterosexual
promiscuity. None of the patients were receiving antituberculosis
or antiretroviral therapy at the time of intake into the study.
Cytokine assay
PBMCs were obtained by density gradient centrifugation on
Ficoll diatrizoate. The cells were washed with RPMI 1640
medium (Bio-Whittaker, Walkersville, MD), and their viability
count was ascertained by the trypan blue dye exclusion method.
PBMCs were cultured in 24-well tissue culture plates (Falcon,
Lincoln Park, NJ) at a concentration of 2 3 106 cells/well in a
volume of 1 ml RPMI 1640 medium supplemented with 1 mM
L-glutamine, 80 mg/ml gentamicin, 25 mM HEPES, and 10%
fetal bovine serum (FBS). The cells were stimulated in vitro
with two mycobacterial antigens and a mitogen. The antigens
used were purified protein derivative (PPD) (Conaught, Wil-
lowdale, Ontario, Canada) and heat-killed M. tuberculosis
H37Rv (Hk-M.tb.) (prepared in our laboratory). The mitogen
used was phorbol myristate acetate (PMA) (Calbiochem, San
Diego, CA) in combination with ionomycin (Calbiochem). PPD
was used at a concentration of 10 mg/ml, Hk-M.tb. at 10 mg/ml,
PMA at 50 ng/ml, and ionomycin at 1 mg/ml. The cell culture
supernatants were collected after 24 h for estimation of IL-10,
IL-12, and IL-18 and after 72 h for estimation of IFN-g. Con-
centrations of the antigens and mitogen used and the duration
of culture were found previously to give optimal cytokine re-
sponses in our laboratory. The cell culture supernatants were
stored at 270°C until use. Cytokines were measured by cap-
ture ELISA using kits purchased from Immunotech (Coulter,
Hialeah, FL). To rule out technical error, about 10% of all the
samples were run in duplicate, and the paired results were com-
pared for concurrence.
Immunophenotyping
The monoclonal antibodies (mAbs) used for immunopheno-
typing were anti-CD14, anti-CD45, anti-CD3, anti-CD4, and
anti-CD8. Irrelevant isotope-matched antibodies (mouse IgG1
and mouse IgG2a) were included as controls for nonspecific
immunofluorescence. All the mAbs were directly conjugated
with either fluorescein isothiocyanate (FITC) or phycoerythrin
(PE) and were purchased from Becton Dickinson Immunocy-
tometry (Mountain View, CA).
Lymphocyte subpopulations were analyzed in whole blood
by dual-color flow cytometry using the standard staining pro-
tocol. The cells were analyzed on a FACSort flow cytometer
(Becton Dickinson) using CellQuest software. Data were col-
lected per 10,000 cells for each tube and analyzed as dot-plots.
Statistical analysis
All results are expressed as mean 6 SE. Wherever neces-
sary, log transformation was used to stabilize variance. Com-
parison of the means between any two groups was performed
using unpaired t-test. The four groups were compared simulta-
neously using analysis of variance (ANOVA). Tukey’s multi-
ple comparison test was also used to classify the groups. The
significance was fixed at the 5% level.
RESULTS
Routine hematologic and biochemical tests as well CD41
cell counts were performed for all study subjects. HIV-infected
patients had significantly lower CD41 cell counts than HIV-
negative patients (284 6 56 cells/ml vs. 758 6 53 cells/ml, p ,
0.001) (Table 1). Based on the CD4 counts, both groups of HIV
patients (categories 1 and 3) were further divided into two sub-
groups, those having CD4 counts .200 cells/ml and those with
CD4 counts ,200 cells/ml. Each of these subgroups had more
or less equal numbers of patients. Thus, there were six groups
(I, II, III, IV, V, VI).
IFN-g in plasma and in supernatants of mycobacterial
antigen-stimulated PBMCs
Antigen-induced IFN-g production was measured in the su-
pernatants of PBMCs cultured with PPD or Hk-M.tb. for 72 h.
Mean IFN-g levels in mycobacterial antigen-stimulated cell cul-
tures for TB patients were 2-fold higher than the correspond-
ing values for healthy controls (Table 1). A trend toward a de-
cline in IFN-g production was observed in patients co-infected
with HIV. Very small amounts of IFN-g were measured in cul-
ture supernatants of HIV patients without active TB. Although
plasma IFN-g levels were higher in patients with either TB or
HIV than in healthy controls, this increase did not reach statis-
tical significance. Among HIV patients with advanced disease,
low CD4 counts (,200 cells/ml), and active TB, there was a
significant increase in the amount of circulating IFN-g (p ,
0.05). On the other hand, in HIV patients with moderate CD4
counts (200–500 cells/ml) and active TB, circulating IFN-g lev-
els were not elevated to the same extent.
IL-12 in plasma and in supernatants of in vitro
stimulated PBMCs
PBMCs of TB patients produced significantly higher
amounts of IL-12 in response to in vitro stimulation with PPD
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compared with healthy controls (p , 0.005) (Table 2). HIV co-
infection in TB patients resulted in a significant decrease in IL-
12 production in response to PPD (p , 0.005). Though Hk-
M.tb.-induced IL-12 production was also lower in HIV-positive
TB patients compared with TB patients without HIV infection,
the difference between the groups was not statistically signifi-
cant. PBMCs of HIV-positive individuals without TB produced
very low amounts of IL-12 in response to mycobacterial anti-
gens in vitro. Plasma IL-12p70 levels did not differ significantly
in any of the study groups. However, a trend toward an increase
in circulating IL-12 levels was observed in HIV-infected TB
patients, particularly the group with low CD4 counts, compared
with those with TB alone.
IL-18 in plasma and in supernatants of in vitro
stimulated PBMCs
No significant difference was observed in IL-18 production
in PPD and Hk-M.tb.-stimulated cultures of PBMCs from
healthy controls and from patients (Table 3). Mean IL-18 con-
centrations in cell culture supernatants of TB patients were sim-
ilar irrespective of the presence or absence of HIV infection.
PBMCs of HIV-positive individuals without TB produced very
low amounts of IL-18. Plasma IL-18 levels were significantly
higher in TB patients than in healthy controls (p , 0.001). Pa-
tients with both HIV and TB (irrespective of CD4 counts) had
significantly higher IL-18 levels than the other four groups (p ,
0.01).
IL-10 in plasma and in supernatants of in vitro
stimulated PBMCs
PPD-induced IL-10 production was highly variable and not
significantly different in any of the study groups. However, Hk-
M.tb. induced significantly higher production of IL-10 in indi-
viduals with TB compared with healthy controls (p , 0.001)
(Table 4). Both among HIV patients with moderate CD4 counts
(200–500 cells/ml) and those with low CD4 counts (,200
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TABLE 1. IFN-g LEVELS IN PLASMA AND CULTURE SUPERNATANTS OF IN VITRO STIMULATED PBMCS
Hk-M.tb.-
CD4 counts PPD-stimulated stimulated Plasma
Group Subjects (cells/ml) PBMC (pg/ml) PBMC (pg/ml) (pg/ml)
I HIV 1 TB 1 284 6 20a 280.8 6 124.0 333.2 6 128.8 31.0 6 10.1
(n 5 14) (CD4 . 200)
II HIV 1 TB 1 89 6 16 409.4 6 275.0 170.5 6 87.3 91.6 6 25.1*
(n 5 15) (CD4 , 200)
III TB 1 609 6 56 730.2 6 184.5 799.1 6 438.5 23.6 6 5.1
(n 5 21)
IV HIV 1 TB 2 432 6 76 1.8 6 0.4 15.2 6 6.8 36.0 6 32.2
(n 5 14) (CD4 . 200)
V HIV 1 TB 2 63 6 10 4.1 6 2.0 5.4 6 2.4 39.7 6 8.2
(n 5 12) (CD4 , 200)
VI Healthy 758 6 53 323.3 6 130.4 279.5 6 135.7 7.5 6 1.5
(n 5 22) controls
aMean 6 SE.
*p , 0.05 compared with all other groups.
TABLE 2. IL-2 LEVELS IN PLASMA AND CULTURE SUPERNATANTS OF IN VITRO STIMULATED PBMCS
Hk-M.tb.-
PPD-stimulated stimulated Plasma
Group Subjects PBMC (pg/ml) PBMC (pg/ml) (pg/ml)
I HIV 1 TB 1 9.1 6 2.9a,* 17.0 6 5.3 15.4 6 4.2
(CD4 . 200)
II HIV 1 TB 1 4.7 6 1.4* 13.6 6 4.4 41.1 6 14.5
(CD4 , 200)
III TB 1 16.9 6 3.0** 39.2 6 15.0 9.2 6 2.1
IV HIV 1 TB 2 5.9 6 2.2 17.6 6 1.5 5.2 6 1.9
(CD4 . 200)
V HIV 1 TB 2 13.6 6 1.2 3.5 6 0.1 17.8 6 3.6
(CD4 , 200)
VI Healthy 3.6 6 0.7 30.3 6 13.0 8.0 6 1.8
controls
aMean 6 SE.
*p , 0.005 compared with group III.
**p , 0.005 compared with group VI.
cells/ml), patients with TB produced significantly higher
amounts of IL-10 in response to Hk-M.tb. compared with those
without active TB (p , 0.05). No statistically significant dif-
ferences were observed in plasma IL-10 levels in any of the
study groups.
DISCUSSION
To our knowledge, this is the first study to simultaneously
evaluate both mycobacterial antigen-induced cytokine produc-
tion by PBMCs in vitro and their plasma concentrations in pa-
tients with both HIV and TB. Many investigators have evalu-
ated cytokine levels either in plasma or in culture supernatants
of PBMCs obtained from patients with HIV or TB,(10–12) but
only a few have measured IFN-g levels in patients with dual
infection.(13,14) We found that in TB patients with HIV infec-
tion, in vitro IFN-g production in response to mycobacterial
antigens was variable but tended to be lower than in TB pa-
tients without HIV infection. Elliott et al.(14) also reported pro-
foundly impaired IFN-g responses to mycobacterial antigens in
HIV patients with TB. Depression of in vitro immune responses
in patients with dual infection could be the result of either the
loss of antigen-specific cells or their reduced response to stim-
ulation with mycobacterial antigens. In contrast, plasma levels
of IFN-g were significantly higher in HIV-infected TB patients
with low CD4 counts (,200 cells/ml) than in HIV-negative TB
patients as well as in HIV-positive TB patients with higher
CD41 cell counts, indicating that immune activation is maxi-
mal in patients with advanced HIV infection and TB.
These observations indicate that plasma cytokine levels do
not reflect M. tuberculosis-induced cytokine production by
PBMCs, and vice versa. A similar finding has been reported re-
cently in TB patients by Vankayalapati et al.,(15) suggesting that
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TABLE 4. IL-10 LEVELS IN PLASMA AND CULTURE SUPERNATANTS OF IN VITRO STIMULATED PBMCS
Hk-M.tb.-
PPD-stimulated stimulated Plasma
Group Subjects PBMC (pg/ml) PBMC (pg/ml) (pg/ml)
I HIV 1 TB 1 446.7 6 112.7a 4525.2 6 482.9* 6.3 6 2.0
(CD4 . 200)
II HIV 1 TB 1 378.1 6 281.4 3028.9 6 500.6** 17.8 6 3.9
(CD4 , 200)
III TB 1 393.7 6 165.2 3792.1 6 319.3*** 7.8 6 3.3
IV HIV 1 TB 2 140.0 6 50.6 1258.0 6 513.6 24.0 6 5.2
(CD4 . 200)
V HIV 1 TB 2 53.3 6 42.8 741.7 6 234.6 16.7 6 5.3
(CD4 , 200)
VI Healthy 225.8 6 84.1 1683.1 6 351.3 24.8 6 2.9
controls
aMean 6 SE.
*p , 0.05 compared with group IV.
**p , 0.05 compared with group V.
***p , 0.05 compared with group VI.
TABLE 3. IL-18 LEVELS IN PLASMA AND CULTURE SUPERNATANTS OF IN VITRO STIMULATED PBMCS
Hk-M.tb.-
PPD-stimulated stimulated Plasma
Group Subjects PBMC (pg/ml) PBMC (pg/ml) (pg/ml)
I HIV 1 TB 1 138.3 6 92.7a 204.4 6 124.5 1191.6 6 139.1*
(CD4 . 200)
II HIV 1 TB 1 78.3 6 55.5 106.4 6 20.9 1167.8 6 150.5*
(CD4 , 200)
III TB 1 87.5 6 26.2 236.6 6 49.3 767.8 6 240.0**,***
IV HIV 1 TB 2 5.5 6 5.1 5.5 6 2.9 635.5 6 79.7**,***
(CD4 . 200)
V HIV 1 TB 2 11.2 6 0.1 12.5 6 4.7 790.6 6 64.5**,***
(CD4 , 200)
VI Healthy 92.2 6 25.2 99.1 6 31.3 333.7 6 63.5*,**,***
controls
aMean 6 SE.
*p , 0.01 compared with group III.
**p , 0.05 compared with group I.
***p , 0.05 compared with group II.
serum cytokine levels do not parallel M. tuberculosis-induced
cytokine production by PBMCs. It has been demonstrated that
T cells and macrophages at the site of disease in TB have the
capacity to produce IFN-g, and increased local vascular per-
meability is likely to favor diffusion of cytokines into the blood-
stream.(15) It is, therefore, speculated that elevated plasma lev-
els of IFN-g and its regulatory cytokines in patients with HIV
and TB are caused by their leakage from tissues into the cir-
culation.
Production of IFN-g by T cells depends on the synergistic
effects of the monokines IL-12 and IL-18, both of which are
believed to be necessary for full expression of Th1 re-
sponses.(16–18) IL-12 is produced by various cell types, such as
phagocytic cells, dendritic cells (DC), and B lymphocytes, and
induces the production of IFN-g from T cells and natural killer
(NK) cells after binding to its own receptor.(19) Like IL-12, IL-
18 is synthesized by various cell types and synergizes with IL-
12 in the enhancement of NK cell cytotoxicity and of T cell
proliferation, as well as the induction of IFN-g production by
T cells, particularly CD41 cells.(19) In our study, lower amounts
of IL-12 were produced by PBMCs of patients with HIV and
TB compared with those with TB alone in response to both the
mycobacterial antigens used. The difference was found to be
statistically significant, however, only with PPD and not with
Hk-M.tb., probably because of the purified and specific nature
of PPD compared with the crude Hk-M.tb. antigen. There was
no significant difference in plasma levels of IL-12 between TB
patients with and without HIV co-infection, although there was
a trend toward an increase in IL-12 levels in patients with se-
vere immunodeficiency. In contrast, although IL-18 production
by PBMCs was not significantly different between the HIV-
positive and HIV-negative TB patients, plasma IL-18 levels
were higher in individuals with dual infection compared with
those with TB alone. Mayanja-Kizza et al.(20) studied in vivo
levels of IL-12 and IL-18 in HIV-infected and uninfected pa-
tients with TB and reported findings similar to ours.
IL-10, a cytokine produced by macrophages, is a potent im-
munosuppressive factor. Some intracellular pathogens specifi-
cally target macrophages for infection and use IL-10 to dampen
the host immune response and stall their elimination from the
host.(21) We found that although in vitro production of IL-10 in
response to PPD was not significantly different in any of the
study groups, Hk-M.tb. induced significantly higher production
of IL-10 in HIV patients with TB than in HIV patients without
TB. Patients with HIV infection have been shown to have higher
IL-10 production in response to Mycobacterium avium anti-
gen.(22) Plasma IL-10 levels in the different study groups var-
ied considerably and did not show statistical significance, al-
though the lowest levels were seen in HIV-uninfected TB
patients. In the literature, increased levels of plasma IL-10 have
been associated with adult HIV disease progression, with the
highest levels in patients with the most advanced disease.(23)
Surprisingly, high levels of plasma IL-10 were detected in the
healthy controls included in our study. A probable explanation
for this phenomenon could be the high prevalence of and con-
sequently high exposure to parasitic, helminthic, and other trop-
ical diseases. Lukwiya et al.(24) reported an increased frequency
of IL-10-producing cells in both HIV-infected Africans and un-
infected Africans compared with Italian controls. Yet another
study described high levels of plasma IL-10 in healthy contacts
of TB patients.(25) Because the healthy controls included in our
study were laboratory workers from a TB hospital who had pro-
longed exposure to TB, their immune response could be simi-
lar to that of contacts of TB patients. However, this finding
needs to be confirmed in larger groups of individuals with and
without contact with TB. In addition, the role of IL-10 in mod-
ifying disease progression in HIV-infected patients in India
needs further study.
In summary, we have demonstrated significant immune ac-
tivation, as seen by high plasma IFN-g, IL-12, and IL-18, in
patients dually infected with TB and HIV compared with those
with either infection alone. The Th1 arm of the immune sys-
tem appears to be maximally stimulated, particularly in indi-
viduals with advanced HIV disease, and this is likely to be a
double-edged sword. It is, therefore, unlikely that further stim-
ulation of T lymphocytes will be beneficial, whereas the effect
of antagonizing these cytokines is still unknown. Although the
findings of our study reveal an active inflammatory response
in vivo, a downregulation of the in vitro immune response was
observed in patients with TB and HIV.
The present study has a few limitations. These include a rel-
atively small sample size in each study group, heterogeneity of
the HIV-positive TB-negative group, and lack of information
on the PPD status of the study subjects. Although it is not pos-
sible to draw definitive conclusions at this stage on the signif-
icance of circulating cytokines as a predictor of activation state,
our study provides preliminary evidence on the high levels of
circulating Th1 cytokines in patients with advanced HIV dis-
ease and TB. Further research is needed into the mechanisms
of cytokine dysregulation in HIV-infected patients and also the
impact of treatment of both HIV and TB on cytokine produc-
tion. Plasma levels of IFN-g and IL-18 or their surrogate mark-
ers need to be studied longitudinally in order to correlate them
with disease outcome.
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